|

KN026 Clinical Trials

3 actively recruiting trials

No change since May 2026

Pipeline

Phase 2: 1Phase 3: 2

Top Sponsors

  • Shanghai JMT-Bio Inc.2
  • Peking University1

Indications

  • Cancer3
  • Breast Cancer2
  • Resectable HER2-positive Breast Cancer1
  • Early or Locally Advanced HER2-positive Breast Cancer1
  • HER2-positive Locally Advanced Resectable Gastric Cancer1

Other3 trials

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Phase 3
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
Phase 3
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.